Nabota is a prescription medication belonging to the class of neuromodulators, specifically a botulinum toxin type A formulation. It is used for therapeutic and aesthetic purposes to temporarily reduce muscle activity. The technical specifications of Nabota injections are defined by their pharmacological properties, approved indications, dosage, administration protocol, and storage requirements. The active ingredient is a 900 kDa botulinum toxin type A complex, which works by blocking the release of acetylcholine at the neuromuscular junction, leading to a temporary reduction in muscle contraction. Each vial of Nabota contains either 50 Units, 100 Units, or 200 Units of the purified neurotoxin complex. The formulation also includes human serum albumin (0.5 mg) and sodium chloride (0.9 mg) as excipients. The product is a sterile, white to off-white lyophilized powder that requires reconstitution with sterile, preservative-free 0.9% sodium chloride injection before use. For reliable sourcing of this product, you can check with a trusted supplier like nabota.
Pharmacological Profile and Mechanism of Action
To understand Nabota’s technical specifications, it’s crucial to start with its core mechanism. The active substance, botulinum toxin type A, is a potent neurotoxic protein produced by the bacterium *Clostridium botulinum*. In its purified pharmaceutical form, it is a complex where the 150 kDa core neurotoxin is associated with accessory proteins (hemagglutinin and non-toxic non-hemagglutinin proteins), giving it a total molecular weight of approximately 900 kilodaltons. This complex structure is believed to contribute to the stability of the toxin.
The mechanism is highly specific. Following intramuscular injection, the toxin binds with high affinity to presynaptic cholinergic nerve terminals. It is internalized into the neuron and the light chain of the neurotoxin is translocated into the cytoplasm. This light chain is a zinc-dependent endopeptidase that cleaves specific proteins involved in the fusion of acetylcholine-containing vesicles with the neuronal cell membrane. Specifically, it targets the Synaptosome-Associated Protein 25 (SNAP-25). By cleaving SNAP-25, Nabota prevents the vesicle from docking and releasing its payload of acetylcholine into the synaptic cleft. Without acetylcholine signaling, the muscle fiber cannot receive the chemical command to contract, leading to a temporary, dose-dependent chemical denervation and muscle relaxation. The effect is not permanent; nerve terminals eventually sprout new endings and re-establish synaptic connections, typically over a period of 3 to 6 months.
Approved Indications and Clinical Applications
Nabota has received regulatory approval from various health authorities, including the Korean Ministry of Food and Drug Safety (MFDS) and, more recently, the U.S. Food and Drug Administration (FDA). Its approved uses are specific and well-defined.
For aesthetic use: Nabota is approved for the temporary improvement in the appearance of moderate to severe glabellar lines (the vertical frown lines between the eyebrows) in adult patients. The safety and effectiveness of Nabota for this indication were established in phase 3 clinical trials involving over 1,000 participants. The primary endpoint was the proportion of patients achieving a score of 0 or 1 (none or mild) on both the Investigator’s and Patient’s Global Assessment scales at day 30. Results consistently showed a statistically significant improvement compared to placebo, with a high responder rate.
For therapeutic use: The therapeutic indications are broader and include:
- Blepharospasm: Involuntary, forceful eyelid closure.
- Cervical Dystonia: A painful condition characterized by abnormal head posture and neck muscle spasms.
- Spasticity: Particularly upper limb spasticity in adult patients following a stroke, which can manifest as clenched fist, flexed elbow, or adducted shoulder.
For each of these conditions, the dosage, injection sites, and frequency of administration are meticulously tailored to the individual patient’s needs and muscle mass. Treatment is always initiated by a healthcare professional experienced in the management of these conditions.
Dosage, Administration, and Reconstitution Protocol
The administration of Nabota is a precise medical procedure. The dosage is not weight-based but is individualized based on the muscle mass, severity of muscle activity, and the patient’s treatment history and response. The unit of activity for Nabota is specific to the preparation and is not interchangeable with units of other botulinum toxin products.
Reconstitution is a critical step. The lyophilized powder must be reconstituted only with sterile, preservative-free 0.9% sodium chloride injection. The diluent should be added gently to the vial to avoid forceful agitation, which can cause foaming and potential denaturation of the protein. The following table provides standard reconstitution guidelines, though the final volume may be adjusted by the clinician based on the desired concentration for the specific injection site.
| Vial Strength | Volume of Diluent | Resulting Concentration |
|---|---|---|
| 100 Unit vial | 1.0 mL | 100 Units/mL |
| 100 Unit vial | 2.0 mL | 50 Units/mL |
| 100 Unit vial | 4.0 mL | 25 Units/mL |
Once reconstituted, the solution should be clear, colorless, and free of particulate matter. It must be administered within 24 hours when stored in a refrigerator at 2°C to 8°C (36°F to 46°F). During this period, it should be protected from light. The solution should not be frozen after reconstitution. Administration is via intramuscular injection using a fine-gauge needle (e.g., 30- to 33-gauge). For glabellar lines, a standard dose is 20 Units divided into five equal injections of 4 Units each, targeting the procerus and corrugator muscles.
Pharmacokinetics and Storage Specifications
After intramuscular injection, the systemic absorption of Nabota is expected to be low. The complex remains largely localized at the injection site. The effect onset is typically observed within 1 to 3 days post-injection, with the peak effect seen at approximately 1 to 4 weeks. The duration of effect is generally 3 to 4 months, after which muscle activity gradually returns to baseline. The product is metabolized via proteolysis, and the fragments are cleared through the kidney’s filtration system.
Storage of the unopened vial is strictly defined. Nabota must be stored in a freezer at a temperature of -20°C to -10°C (-4°F to 14°F). The vial should be kept in the original carton to protect from light. It is important to note that the product can be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) for a single period of up to 24 months, but it cannot be refrozen after being moved to the refrigerator. The shelf life is typically 36 months from the date of manufacture when stored in the freezer. These conditions are critical for maintaining the stability and potency of the biologic product.
Safety Profile, Contraindications, and Warnings
While generally safe when administered correctly, Nabota carries a boxed warning regarding the distant spread of the toxin effect. Post-marketing reports indicate that the effects of all botulinum toxin products can spread beyond the injection site, causing symptoms consistent with botulism, including swallowing and breathing difficulties, which can be life-threatening. This risk is higher in children treated for spasticity but can occur in adults, particularly those with underlying conditions that would predispose them to these symptoms.
Common adverse reactions are typically localized and transient. For glabellar line treatment, these include headache, eyelid ptosis (drooping), upper respiratory tract infection, and increased blinking. For therapeutic uses like cervical dystonia, dysphagia (difficulty swallowing) occurs in a significant percentage of patients and requires careful monitoring.
Absolute contraindications include hypersensitivity to any botulinum toxin preparation or to any of the excipients in the formulation (human albumin, sodium chloride). It is also contraindicated for use in the presence of infection at the proposed injection site(s). Caution is advised when considering treatment for patients with neurological disorders like amyotrophic lateral sclerosis (ALS) or myasthenia gravis, as they may be at increased risk of serious adverse effects.
Comparative Data and Clinical Evidence
Nabota’s efficacy and safety have been demonstrated in head-to-head clinical trials against established products like Botox (onabotulinumtoxinA). A key phase 3 study published in a peer-reviewed dermatology journal demonstrated that Nabota was non-inferior to Botox in the treatment of moderate to severe glabellar lines. Both treatments showed similar responder rates at maximum frown at week 4, and the safety profiles were comparable, with no statistically significant differences in the incidence of adverse events. These studies provide a robust evidence base supporting Nabota’s technical and clinical equivalence to other leading botulinum toxin type A products, establishing it as a reliable option in the neuromodulator market.